With 173,000 senior citizens calling Ocean County home, the Board of Chosen Freeholders is making certain programs and services tailored to their ever-changing needs are available and easily accessible.
NEW JERSEY CHAMBER OF COMMERCE: Op-Ed: It’s Time to Stop Ignoring the Needs of NJ’s Business Community
The governor wants a fairer economy in New Jersey but companies are bearing the heaviest burden of delivering it.
MERCK: Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has exercised its option to license NGM313, an investigational monoclonal antibody agonist of the β-Klotho/FGFR1c receptor complex that is currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH) and type 2 diabetes.
NEW JERSEY CHAMBER OF COMMERCE: N.J. Chamber of Commerce President Tom Bracken's Statement on State Tax Incentive Programs
To compete in today's economy, states need to have tax incentives.
MERCK: Merck’s KEYTRUDA® (pembrolizumab) Receives Five New Approvals in Japan, Including in Advanced Non-Small Cell Lung Cancer (NSCLC), as Adjuvant Therapy for Melanoma, and in Advanced Microsatellite Instability-High (MSI-H) Tumors
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that KEYTRUDA, Merck’s anti-PD-1 therapy, has simultaneously received five new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA), including three expanded uses in advanced non-small lung cancer (NSCLC), one in melanoma, as well as a new indication in advanced microsatellite instability-high (MSI-H) tumors.